Skip to main content
TPST logo

TPST · Tempest Therapeutics, Inc.

Track TPST — free
$0.33 -0.01 (-4.24%) At close · Nov 17
Market Cap
$6.54M
Shares
20.00M
Volume · Nov 17 183.16K Avg daily vol (3M) 2.52M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.33 Open$0.34 Day$0.30–0.34 52W close$0.33–9.38 Avg vol 30d206K Short int241K · 1.2% of shares · 1.9d Short vol27% DataJan 2020–Nov 2026 Filing10-Q · Nov 13

Latest documents

2026
Nov 16
Proxy statement DEFA14A
Special Meeting on Charter Amendment Adjourned to December 11

Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, lacking votes to approve a charter amendment replacing supermajority voting and allowing written consent. A quorum was present, with 74.64% of outstanding shares.

4 source passages
The Special Meeting will reconvene on December 11, 2026 at 12:00 p.m. Eastern Time via live webcast because there were not sufficient votes to approve the Proposal at the time of the Special Meeting to replace specified supermajority voting requirements and permit stockholder action by written consent a total of 11,052,422 shares, or 74.64% of the 14,806,997 shares of common stock outstanding as of May 28, 2026 Open the document at this passage
Nov 16
Current report 8-K Events of Nov 12
Special Meeting Adjourned to December 11 Over Insufficient Votes

Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, after not having enough votes to approve a charter amendment replacing supermajority voting and allowing stockholder written consent. A quorum of 74.64% of shares was present.

Shareholder vote results, Other events
4 source passages
The Special Meeting will reconvene on December 11, 2026 at 12:00 p.m. Eastern Time via live webcast because there were not sufficient votes to approve the Proposal at the time of the Special Meeting a total of 11,052,422 shares, or 74.64% of the 14,806,997 shares of common stock outstanding as of May 28, 2026 to replace specified supermajority voting requirements and permit stockholder action by written consent Open the document at this passage
Nov 13
Current report 8-K
Cash falls to $0.9 million with going-concern doubt

Tempest Therapeutics reported $0.9 million in cash, substantial doubt about continuing as a going concern and expected funding for less than 12 months. It licensed TPST-4903 and secured an equity line of credit of up to $50.0 million.

Financial results
5 source passages
Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced in vivo chimeric antigen receptor T-cell (“CAR-T”) product candidates to treat cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and provided a business update. Tempest ended the quarter with $0.9 million in cash and cash equivalents, compared to $7.7 million on December 31, 2025. The Company’s existing cash and cash equivalents are expected to fund its projected operating expense requirements for less than 12 months from the date the financial statements were available to be issued, and there is substantial doubt about the Company’s ability to continue as a going concern. Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 Secured access to additional capital through an equity line of credit with Lincoln Park Capital Fund of up to $50.0 million and a private placement with gross proceeds of approximately $2.5 million Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash expected to fund under 12 months; Nasdaq deadline extended

Tempest reported $0.9 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern, with cash expected to fund operations for less than 12 months. Nasdaq extended its compliance deadline to November 16, 2026.

Net loss $3.63M Diluted EPS -$0.21
Read from the MD&A section
3 source passages
As of September 30, 2026, we had cash and cash equivalents totaling $0.9 million compared to $7.7 million as of December 31, 2025. We expect that our existing cash and cash equivalents will fund our projected operating expense requirements through less than 12 months from the date our condensed consolidated financial statements were available to be issued. Accordingly, there is substantial doubt regarding our ability to continue as a going concern for a period of 12 months from the date of the issuance of the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q. On October 30, 2026, Nasdaq staff has granted us an extension of time to regain compliance until November 16, 2026. Open the document at this passage
Nov 12
Current report 8-K Events of Nov 11
Exercises Exclusive License Outside China After Early CAR-T Results

Tempest Therapeutics exercised its option on November 11, 2026 to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform worldwide, excluding China, after encouraging preliminary results in 13 relapsed or refractory multiple myeloma patients.

Regulation FD disclosure, Other events
2 source passages
BRISBANE, Calif., November 11, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that it has exercised its option under its agreement with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”) to obtain an exclusive license to develop and commercialize Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, excluding China. Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$40.59M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$897,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+280.8%
Year over year · more shares
Price change (1Y)
-96.5%
Trailing year
Short interest
1.2%
Latest settlement · 1.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −76%
below
Price vs 50-day avg −50%
below
RSI (14) 23
oversold
MACD trend Positive
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −43%
trailing
6-month return −81%
trailing
YTD return −89%
this year
Relative strength −78%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.21% of shares out · ▼ -22.9% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
24 holders — mid 3-yr range
Squeeze score 41
elevated · 0–100
Fundamentals
Fair
Revenue growth −55%
Y/Y
EPS growth +68%
Y/Y
Free cash flow $-26.8M
Balance sheet $23.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 127%
annualized · 1-yr
Max drawdown −97%
past year
ATR 16.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−76% Bearish
Price vs 50-day avg
−50% Bearish
RSI (14)
23 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.21% of shares out · ▼ -22.9% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
24 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $9
vs 200-day avg -76% vs 50-day avg -50%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash used in operating activities 12.4M nine months ended September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TPST
Tempest Therapeutics, Inc.
this stock
$6.54M -88.6% -54.8% — 1.2%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
24
% held
4.1%
Net QoQ
-475.6K sh
Top holder
Versant Venture Managemen…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
241.2K
Days to cover
1.9d
Change
-71.8K sh
View
Short Volume
Short vol %
27%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
2.2K
Value
$1.1K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
59.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$295.0K
Net income (FY)
$-26.3M
EPS diluted
$-6.33
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
54

Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, after not having enough votes to approve a charter amendment replacing supermajority voting and allowing stockholder written consent. A quorum of 74.64% of shares was present.

View
Proposed Sales
Value
$427.0K
Shares
388.0K
Filed
Aug 13, 2024
View
Exempt Offerings
Offering
$7.5M
Filed
Oct 14, 2026
View
Earnings & Events
Investor Relations
Latest news
Tempest Reports Third Quarter 202…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
TPST -12.5% -43.2% -81.1% -34.0% -88.6%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -10.2% -38.4% -78.1% -30.9% -96.0%
Key facts CIK 1544227 CUSIP 87978U207 13F (30d) 38 filings 24 filers Visit website Investor relations